共 30 条
- [1] Lee YJ(2010)Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer Cancer 116 1336-1343
- [2] Choi HJ(2013)Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2385-2394
- [3] Kim SK(2013)Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement J Thorac Oncol 8 e30-e31
- [4] Shaw AT(2014)Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC Ann Oncol 25 415-422
- [5] Kim DW(2013)The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer J Thorac Oncol 8 1570-1573
- [6] Nakagawa K(2014)Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK +) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial J Clin Oncol 32 5S-e445
- [7] Maillet D(2011)CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib J Clin Oncol 29 e443-1128
- [8] Martel-Lafay I(2014)Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study Lancet Oncol 15 1119-236
- [9] Arpin D(2015)Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib J Thorac Oncol 10 232-1028
- [10] Ou SH(2014)Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases Cancer Chemother Pharmacol 74 1023-undefined